In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci

被引：8

作者：

Bergeret, M ^{[1
]}

Boutros, N ^{[1
]}

Raymond, J ^{[1
]}

机构：

[1] Univ Paris 05, Hop St Vincent de Paul, Microbiol Serv, F-75014 Paris, France

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2004年 / 23卷 / 03期

关键词：

cefpirome; decreased susceptibility to glycopeptides; coagulase-negative staphylococci; GISA;

D O I：

10.1016/j.ijantimicag.2003.08.009

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Infections caused by coagulase-negative staphylococci are becoming increasingly important, particularly those of nosocomial origin, as the organisms are frequently multi-resistant. New antimicrobial strategies are needed. The bactericidal activity of a combination of cefpirome with either vancomycin or teicoplanin against 12 strains of methicillin-resistant staphylococci with a decreased susceptibility to teicoplanin was determined in vitro by a time killing method. Strains Mu3 and Mu50 of Staphylococcus aureus were also studied. Cefpirome (0.125-0.5 x MIC) combined with vancomycin (0.25-1 x MIC) or teicoplanin (0.125-1 x MIC) acted synergically against 12 isolates over 18 h in most cases. A synergistic killing effect was also observed with the Mu3 and Mu50 strains of glycopeptide-intermediate S. aureus but over a longer period. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：247 / 253

页数：7

共 39 条

[1] ANALYSIS OF VANCOMYCIN TIME-KILL STUDIES WITH STAPHYLOCOCCUS SPECIES BY USING A CURVE STRIPPING PROGRAM TO DESCRIBE THE RELATIONSHIP BETWEEN CONCENTRATION AND PHARMACODYNAMIC RESPONSE [J].

ACKERMAN, BH ;

VANNIER, AM ;

EUDY, EB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1766-1769

[2] Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin [J].

Aritaka, N ;

Hanaki, H ;

Cui, LZ ;

Hiramatsu, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1292-1294

[3] INVITRO ANTIMICROBIAL ACTIVITY OF IMIPENEM IN COMBINATION WITH VANCOMYCIN OR TEICOPLANIN AGAINST STAPHYLOCOCCUS-AUREUS AND STAPHYLOCOCCUS-EPIDERMIDIS [J].

BARR, JG ;

SMYTH, ETM ;

HOGG, GM .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1990, 9 (11) :804-809

[4] In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus [J].

Bergeret, M ;

Raymond, J .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (02) :291-294

[5] Neonatal bacteremia: Patterns of antibiotic resistance [J].

Bromiker, R ;

Arad, I ;

Peleg, O ;

Preminger, A ;

Engelhard, D .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2001, 22 (12) :767-770

[6] Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin [J].

Climo, MW ;

Patron, RL ;

Archer, GL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1747-1753

[7] Survey of infections due to Staphylococcus species:: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].

Diekema, DJ ;

Pfaller, MA ;

Schmitz, FJ ;

Smayevsky, J ;

Bell, J ;

Jones, RN ;

Beach, M .

CLINICAL INFECTIOUS DISEASES, 2001, 32 :S114-S132

[8] Vancomycin and oxacillin synergy for methicillin-resistant staphylococci [J].

Domaracki, BE ;

Evans, AM ;

Venezia, RA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (05) :1394-1396

[9]

DRUGEON HB, 17 INT C CHEM BERL 2

[10] Nosocomial bloodstream infections in United States hospitals: A three-year analysis [J].

Edmond, MB ;

Wallace, SE ;

McClish, DK ;

Pfaller, MA ;

Jones, RN ;

Wenzel, RP .

CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :239-244

← 1 2 3 4 →